Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting

GlobeNewswire November 1, 2018

Agios Reports Third Quarter 2018 Financial Results

GlobeNewswire November 1, 2018

Agios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018

GlobeNewswire October 18, 2018

Agios Announces Chief Executive Officer Succession Plan

GlobeNewswire September 4, 2018

Agios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018

GlobeNewswire August 28, 2018

Agios Reports Second Quarter 2018 Financial Results

GlobeNewswire August 2, 2018

Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018

GlobeNewswire July 23, 2018

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

GlobeNewswire July 20, 2018

Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals, Roadrunner Transportation, and OSI — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire June 29, 2018

Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China

GlobeNewswire June 26, 2018

Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

GlobeNewswire June 18, 2018

New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients

GlobeNewswire June 4, 2018

Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent

GlobeNewswire June 2, 2018

Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors

GlobeNewswire June 1, 2018

Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire May 17, 2018

Agios to Present New Clinical Data from its IDH Programs at ASCO

GlobeNewswire May 16, 2018

Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day

GlobeNewswire May 4, 2018

Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018

GlobeNewswire April 11, 2018

Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion

GlobeNewswire March 19, 2018

Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018

GlobeNewswire March 5, 2018